Peru
July 2015
Key Market Facts
- South Korea's record-breaking licensing deals in 2015-2016 — with Hanmi Pharmaceutical and other Korean companies signing multi-billion dollar deals with global pharmaceutical companies — signalled Korea's emergence as a genuine source of pharmaceutical innovation.
- Peru's pharmaceutical market is served primarily by imports and multinational subsidiaries, with limited domestic manufacturing. Key multinational companies including Pfizer, Novartis, Sanofi, Bayer, and Abbott all maintain Peruvian commercial operations.
- Regulatory authority: DIGEMID (Directorate General of Medicines, Inputs and Drugs) under the Ministry of Health oversees pharmaceutical regulation and drug approvals in Peru.
- Peru's universal health insurance coverage has been gradually expanding through SIS (Seguro Integral de Salud) and EsSalud, increasing pharmaceutical expenditure and market size, though coverage remains incomplete compared to regional peers.
- Peru's pharmaceutical market in 2017 was navigating the political uncertainty following the Odebrecht corruption scandal, which implicated senior government officials and created broader economic uncertainty affecting healthcare investment and pharmaceutical policy.
Back
